Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07228364 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
A Phase 1 study of Autosomal Dominant Polycystic Kidney Disease, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 15
- Study locations
NCT07228364: Recruiting Phase 1 study of Autosomal Dominant Polycystic Kidney Disease, sponsored by AstraZeneca.
NCT07228364 is a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 40 participants, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07228364, a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 15
- Study locations
Study Summary
A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
Primary Outcome
Number of participants with at least one TEAE and SAE, including events leading to discontinuation or death; coded by system organ class and preferred term. Unit: participants.
Conditions Studied
Interventions
- DRUG AZD1613 - Part A
- DRUG Placebo - Part A
- DRUG AZD1613 - Part B
- DRUG Placebo - Part B
Study Locations (15)
Other
- Research Site - Chengdu
- Research Site - Hangzhou
- Research Site - Nanjing
- Research Site - Shanghai
- Research Site - Wuhan
- Research Site - Xiamen
- Research Site - London
Florida
- Research Site - Jacksonville
- Research Site - Orlando
Alabama
- Research Site - Birmingham
California
- Research Site - Loma Linda
Kansas
- Research Site - Lenexa
Maryland
- Research Site - Baltimore
Minnesota
- Research Site - Rochester
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-01-04 |
| Phase | Phase 1 |
What NCT07228364 shows while recruiting
NCT07228364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which AZD1613 - Part A is the first listed.
NCT07228364 lists 15 locations in 8 states (Other, Florida, Alabama).
Frequently Asked Questions
What is clinical trial NCT07228364 about?
NCT07228364 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease". A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).
What is the current status of trial NCT07228364?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-11-10. Estimated completion is 2027-01-04.
What conditions does trial NCT07228364 study?
This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.
What interventions are being tested in trial NCT07228364?
The interventions under investigation include: AZD1613 - Part A (DRUG), Placebo - Part A (DRUG), AZD1613 - Part B (DRUG), Placebo - Part B (DRUG).
Who is sponsoring clinical trial NCT07228364?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07228364 being conducted?
This trial has 15 study locations across Alabama, California, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autosomal Dominant Polycystic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07228364's enrollment target sits among peer trials
40 7th of 9 higher than 2 of 9 other Autosomal Dominant Polycystic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autosomal Dominant Polycystic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING
-
NOX4 and Related Biomarkers in ADPKD
RECRUITING
-
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING · Phase 2
-
A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD
ACTIVE NOT RECRUITING
-
Intrarenal Microvasculature in ADPKD
ACTIVE NOT RECRUITING
-
Role of ROS and cAMP-PKA Biomarkers in ADPKD
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI